The abstract is read at the publisher; the summary is JClub's.
In unselected colorectal cancer patients, multigene germline panel testing detects any pathogenic or likely pathogenic variant in 15·2% (95% CI 12·8–18·1; 1061/6925).
- Why it matters: The diagnostic yield of multigene germline panel testing in colorectal cancer is uncertain, limiting how broadly such testing should be offered beyond early-onset cases.
- What they did: A systematic review and meta-analysis of 21 English studies (k=12 for the primary outcome) pooled next-generation sequencing panel results across 6925 individuals, stratifying by age and variant penetrance.
- The result: Yield declines with age but stays above 5% for high-penetrance variants up to age 67 years (95% CI 59–75), and family history of colorectal cancer is linked to higher overall and colorectal cancer-specific yields.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.